 NEW YORK and BERLIN, Sept. 14, 2021 GLOBE NEWSWIRE -- Perception Neuroscience Perception, an atai Life Sciences atai biopharmaceutical company focused on developing innovative therapies in neuropsychiatric diseases, today announced the initiation of a Phase 2a clinical study to evaluate the safety and efficacy of PCN-101 R-ketamine. R-ketamine is a stereoisomer of ketamine being developed for therapeutic treatment of psychiatric disorders such as Treatment Resistant Depression TRD. The Phase 2a clinical trial has received the necessary regulatory and ethics approvals to initiate the study. 